Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Charles E. Geyer(Magee-Womens Hospital), Tanja Španić(Unknown), Judy E. Garber(Dana-Farber Cancer Institute), Judith M. Bliss(Institute of Cancer Research), Sue Friedman(Facing Our Risk of Cancer Empowered), L.E. Fein(Instituto de Oncología de Rosario), Frederik Marmé(Heidelberg University), Amal Arahmani(Breast International Group), Christian F. Singer(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Manuel Taboada(AstraZeneca (Brazil)), Gursel Aktan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Karen Cui(Université Paris Cité), Larissa A. Korde(National Cancer Institute), Oskar T. Johannsson(Lapland Central Hospital), Kelly‐Anne Phillips(The University of Melbourne), Richard D. Gelber(Harvard University), Sunil R. Lakhani(Sullivan Nicolaides Pathology), Priyanka Sharma(Chandigarh University), F. Elsafy(AstraZeneca (Brazil)), Anne Armstrong(The Christie NHS Foundation Trust), Elżbieta Senkus(Gdańsk Medical University), Greg Yothers(University of Pittsburgh), Giovanna Rossi(Istituto Oncologico Veneto), Peter C. Lucas(University of Pittsburgh), Barbro Linderholm(Karolinska University Hospital), Susan M. Domchek(University City Science Center), Anitra Fielding(AstraZeneca (United States)), Agnes Jager(Erasmus MC Cancer Institute), Andrea Eisen(Sunnybrook Health Science Centre), Karen A. Gelmon(University of British Columbia), Seock‐Ah Im(Seoul National University), Jonas Bergh(Karolinska Institutet), T.-W. Liu(National Health Research Institutes), Suzette Delaloge(Institut Gustave Roussy), Mónica Arnedos, Martine Piccart(Université Libre de Bruxelles), Sibylle Loibl(Goethe University Frankfurt), L. Ross(Frontier Agriculture (United Kingdom)), Judith Balmaña(Vall d'Hebron Hospital Universitari), E. Martinez de Dueñas(Consorcio Hospitalario Provincial de Castellón), Robin McConnell(Frontier Agriculture (United Kingdom)), Niklas Loman(Lund University), Simon J. Hollingsworth(AstraZeneca (Japan)), W Janni(Universität Ulm), Zhi-Ming Shao(Fudan University Shanghai Cancer Center), Luca Gianni(Ospedale Infermi di Rimini), James M. Ford(Palo Alto University), Rita K. Schmutzler(University of Cologne), Priya Rastogi(UPMC Hillman Cancer Center)
Cited by 461
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k